Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay
Trial Snapshot
- Phase
- Phase 4
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay
Study Overview
Brief Summary
Currently, drugs commonly used for antiplatelet are aspirin and clopidogrel when encountering stroke or coronary heart disease. In this study, we would use VASP assay and thromboelastograph with platelet mapping assay kit to evaluate the antiplatelet resistance in general population and the relationship between clopidogrel and proton pump inhibitor.
Detailed Description
This study intent is to search the standard to diagnose of the antiplatelet drug resistance and to discover the prevalence of drug resistance in Taiwanese population in Taiwan. The trial will enroll at least 30 healthy people after fulfilling the investigation questionnaire. All the participants will receive antiplatelet drugs in two separate period and measured the efficacy by VASP assay and thromboelastograph with platelet mapping assay. The health volunteer will receive clopidogrel and different types of proton pump inhibitor to see the interference of antiplatelet efficacy between each drug.
Study Design
- Study Type
- Interventional
- Intervention Model
- Crossover
- Primary Purpose
- Screening
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •30 Healthy people, without major systemic disease, not under medication treatment
Exclusion Criteria
- •Systemic disease, under medication control with NSAID, anticoagulants, taking antiplatelet drugs before entering trial, Chinese herb, pregnant or breast feeding woman
Arms & Interventions
Clopidogrel and proton pump inhibitors
all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
Intervention: Clopidogrel and proton pump inhibitors (Drug)
Outcomes
Primary Outcomes
Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay
Time Frame: 6 months
Secondary Outcomes
No secondary outcomes reported